0001437749-26-017034
SEC filingMoleculin reported no revenue and a net loss of $12.8M for Q1 FY2026, widening significantly from $6.4M in Q1 FY2025 — driven primarily by increased clinical trial activity and warrant-related accounting adjustments.
Cash used in operating activities totaled $6.1 million, up from $4.6 million in Q1 FY2025. This reflects the operational cadence of late-stage development: higher near-term outflows tied to trial execution, manufacturing scale-up, and related vendor payments — not a structural shift in burn rate. With no revenue generated, the company remains fully dependent on equity financing and existing cash reserves to fund operations.
Moleculin is a pre-commercial biotechnology company advancing Annamycin, a compound designed to exploit tumor dependence on glucose metabolism — a mechanism also relevant to certain viruses reliant on glycolysis and glycosylation. The absence of revenue is expected and consistent with this developmental stage; all financial results reflect investment in clinical validation rather than commercial execution. As noted in Risk Factors, while the company currently complies with Nasdaq listing standards, there is no assurance that compliance can be maintained in the future.